NCT05256225 2026-06-03Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaNational Cancer Institute (NCI)Phase 3 Recruiting360 enrolled